-

Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research Program

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) recently opened the first Charles River Accelerator and Development Lab (CRADL®) location in Chicago, expanding contract vivarium space for the biopharmaceutical industry in Illinois.

CRADL Chicago is located in Fulton Labs, in the heart of Chicago’s Fulton Market, which is quickly emerging as a hub of the local life sciences community. Fulton Labs also includes premier wet and dry laboratory and office space, offered by Portal Innovations. By offering on-demand facilities, both emerging and established biopharmaceutical companies and research institutions are able to quickly start new projects, accelerating the early stage of research. This allows scientists to focus on research, while leaving the animal husbandry and daily vivarium management to a trusted partner.

The Combined Expertise and Reach of Explora BioLabs and CRADL

With the acquisition of Explora BioLabs in April 2022, the CRADL-Explora Vivarium Network was established as a premier partner for clients to launch or expand their drug research programs, with the added benefit of access to Charles River’s complete portfolio of integrated drug discovery and non-clinical development resources. The CRADL-Explora Vivarium Network operates 28 vivarium facilities, providing over 380,000 square feet of turnkey rental capacity in key biohubs, including Massachusetts, California, Washington, Shanghai, London, and now Illinois. This network supports the growth of the entire biotech ecosystem in each city, allowing researchers to rapidly engage in their research while maintaining the flexibility to relocate or co-locate, knowing they will have reliable, high-quality facilities nearby.

Approved Quotes

  • “Chicago is emerging as a key biohub in the United States, with a growing life sciences community. By providing contract vivarium services, we’re able to support clients in starting projects quickly, without the burden of building infrastructure, which can be costly and time consuming.” –Colin Dunn, Ph.D., Corporate Senior Vice President, Global Research Models & Services, Charles River
  • "Charles River has the largest network of contract vivarium facilities globally, and we're thrilled to have one at our Fulton Market location. Their depth of experience provides an incredible opportunity for the life sciences community in Chicago and other biotech communities. We're glad to have established a relationship with a world-class organization like Charles River, and we look forward to working together in the future.” —John Flavin, Founder and CEO, Portal Innovations

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Media:
Amy Cianciaruso
Corporate Vice President, Chief Communications Officer
781.222.6168
amy.cianciaruso@crl.com

Charles River Laboratories International, Inc.

NYSE:CRL

Release Summary
Charles River recently opened its first location in Chicago, expanding contract vivarium space for the biopharmaceutical industry in Illinois.
Release Versions
$Cashtags
Hashtags

Contacts

Investor:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Media:
Amy Cianciaruso
Corporate Vice President, Chief Communications Officer
781.222.6168
amy.cianciaruso@crl.com

Social Media Profiles
More News From Charles River Laboratories International, Inc.

Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River’s expertise in biologics and cell therapy GMP testing to support MEDIPOST’s global cell therapy pipeline, starting i...

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is com...

Charles River Laboratories Announces First-Quarter 2026 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2026 Financial Results...
Back to Newsroom